← Back to patent-cliff list
Methylprednisolone sodium succinate (Nihon Pharmaceutical)
Tier C — Watch / tradeMethylprednisolone sodium succinate (Nihon Pharmaceutical)
Nihon Pharmaceutical Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Steroid hormone receptor
Indications (approved)：脑炎
Regional status
US
-
EU
-
China
-
Japan
Phase III
2022-03-03
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Methylprednisolone sodium succinate (Nihon Pharmaceutical)?
Approved indications include: 脑炎.
When does the Methylprednisolone sodium succinate (Nihon Pharmaceutical) patent expire?
No public expiry year is available for Methylprednisolone sodium succinate (Nihon Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Methylprednisolone sodium succinate (Nihon Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05